Dicerna Pharma (DRNA) Misses Q4 EPS by 13c, Beats on Revenues

Note: EPS may not be comparable

Dicerna Pharma (NASDAQ: DRNA) reported Q4 EPS of ($0.90), $0.13 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $1.42 million versus the consensus estimate of $1.36 million.

For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• L3Harris CEO steps down amid conduct review, shares drop
• XP Inc eyes US banking license as next business step